These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25131726)

  • 1. Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.
    White B; Madden A; Prins M; Hellard M; Wand H; Dore GJ; Page K; Maher L
    Vaccine; 2014 Sep; 32(42):5460-7. PubMed ID: 25131726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study.
    White B; Dore GJ; Lloyd AR; Rawlinson WD; Maher L
    Med J Aust; 2014 Sep; 201(6):326-9. PubMed ID: 25222455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
    Iversen J; Wand H; McManus H; Dore GJ; Maher L
    Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012.
    Grebely J; Lima VD; Marshall BD; Milloy MJ; DeBeck K; Montaner J; Simo A; Krajden M; Dore GJ; Kerr T; Wood E
    PLoS One; 2014; 9(6):e97726. PubMed ID: 24897109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
    Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    Jacka B; Roy É; Høj S; Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Bruneau J
    J Viral Hepat; 2019 Dec; 26(12):1413-1422. PubMed ID: 31433888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased hepatitis C virus vaccine clinical trial literacy following a brief intervention among people who inject drugs.
    White B; Madden A; Hellard M; Kerr T; Prins M; Page K; Dore GJ; Maher L
    Drug Alcohol Rev; 2013 Jul; 32(4):419-25. PubMed ID: 23113829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
    Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
    Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engaging people who inject drugs in hepatitis C virus testing and prevention through community-based outreach, in Sydney, Australia.
    Coupland H; White B; Bates A; Park JN; Iversen J; Maher L
    Drug Alcohol Rev; 2019 Feb; 38(2):177-184. PubMed ID: 30652363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective study of hepatitis C incidence in Australian prisoners.
    Luciani F; Bretaña NA; Teutsch S; Amin J; Topp L; Dore GJ; Maher L; Dolan K; Lloyd AR;
    Addiction; 2014 Oct; 109(10):1695-706. PubMed ID: 24916002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Housing Stability and Hepatitis C Infection for Young Adults Who Inject Drugs: Examining the Relationship of Consistent and Intermittent Housing Status on HCV Infection Risk.
    Morris MD; Yen IH; Shiboski S; Evans JL; Page K
    J Urban Health; 2020 Dec; 97(6):831-844. PubMed ID: 32901411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short and sporadic injecting cessation episodes as predictors of incident hepatitis C virus infection: findings from a cohort study of people who inject drugs in Montréal, Canada.
    Fortier E; Artenie AA; Zang G; Jutras-Aswad D; Roy É; Grebely J; Bruneau J
    Addiction; 2019 Aug; 114(8):1495-1503. PubMed ID: 30957310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study.
    Valerio H; Alavi M; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Holden J; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Hayllar J; Reid D; Gorton C; Lam T; Dore GJ; Grebely J
    Clin Infect Dis; 2021 Jul; 73(1):e69-e78. PubMed ID: 32421194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus vaccines among people who inject drugs.
    Cox AL; Thomas DL
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S46-50. PubMed ID: 23884065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study.
    Cunningham EB; Hajarizadeh B; Bretana NA; Amin J; Betz-Stablein B; Dore GJ; Luciani F; Teutsch S; Dolan K; Lloyd AR; Grebely J;
    J Viral Hepat; 2017 Sep; 24(9):733-741. PubMed ID: 28256027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.